Infusion Solutions of Delaware – IV Therapy Clinic
Infusion Solutions of Delaware is a IV Therapy Clinic that provides Outpatient Antibiotic Therapy for patients with a variety of infections including osteomyelitis (bone infections), septic arthritis (joint infections), diabetic foot infections, cellulitis, pneumonia, and diverticulitis. Infections caused by common bacteria such as Staphylococcus and Streptococcus, Lyme disease, and bloodstream infections.
Patients will be given their daily dose of antibiotic in our comfortable infusion suite, seven days a week, under close supervision of our registered nurses. Typical antibiotic infusion lasts about 30-60 minutes. Same day infusion appointments may be possible if orders are received before 10 a.m.
Treatment for a variety of rheumatologic diseases (Rheumatoid Arthritis, SLE, Ankylosing Spondylitis, Psoriatic Arthritis), gastrointestinal disorders (Crohn’s disease, Ulcerative Colitis), skin diseases (Psoriasis), gout and refractory uveitis are offered. Typically drugs are infused over one-half to 2 hours every 4-8 weeks starting at 8:00 AM. Late afternoon infusions are also offered. Drugs infused include: infliximab (Remicade), abatacept (Orencia), tocilizumab (Actemra), golimumab (Simponi Aria), vedolizumab (Entyvio), ustekinumab (Stelara), pegloticase (Krystexxa) and rituximab (Rituxan). Certain drugs are mixed and given by injection such as lyophillized certolizimab (Cimzia).
Intravenous ibandronate (Boniva) is offered as an alternative to oral agents for patients with osteoporosis. Treatments are given every three months and take less than five minutes. Please note that there may be manufacturer’s backlog affecting the availability of this drug and it is FDA-approved for use in women only.
Reclast (zoledronic acid) recently became the second IV bisphosphonate FDA approved for the treatment of osteoporosis. Treatments are given annually. Treatments are given annually and it is approved for use in men and women.
Prolia (denosumab) is a prescription medicine used to treat osteoporosis in postmenopausal women and men who:
– are at high risk for fracture, meaning women who have had a fracture related to osteoporosis, or who have multiple risk factors for fracture
– cannot use another osteoporosis medicine or other osteoporosis medicines did not work well